Publication:
Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders.

dc.contributor.authorGarcía-Marchena, Nuria
dc.contributor.authorSilva-Peña, Daniel
dc.contributor.authorMartín-Velasco, Ana Isabel
dc.contributor.authorVillanúa, María Ángeles
dc.contributor.authorAraos, Pedro
dc.contributor.authorPedraz, María
dc.contributor.authorMaza-Quiroga, Rosa
dc.contributor.authorRomero-Sanchiz, Pablo
dc.contributor.authorRubio, Gabriel
dc.contributor.authorCastilla-Ortega, Estela
dc.contributor.authorSuárez, Juan
dc.contributor.authorRodríguez de Fonseca, Fernando
dc.contributor.authorSerrano, Antonia
dc.contributor.authorPavón, Francisco-Javier
dc.date.accessioned2024-01-23T20:13:16Z
dc.date.available2024-01-23T20:13:16Z
dc.date.issued2017-11-06
dc.description.abstractThe identification of growth factors as potential biomarkers in alcohol addiction may help to understand underlying mechanisms associated with the pathogenesis of alcohol use disorders (AUDs). Previous studies have linked growth factors to neural plasticity in neurocognitive impairment and mental disorders. In order to further clarify the impact of chronic alcohol consumption on circulating growth factors, a cross-sectional study was performed in abstinent AUD patients (alcohol group, N = 91) and healthy control subjects (control group, N = 55) to examine plasma concentrations of brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1) and IGF-1 binding protein-3 (IGFBP-3). The association of these plasma peptides with relevant AUD-related variables and psychiatric comorbidity was explored. The alcohol group was diagnosed with severe AUD and showed an average of 13 years of problematic use and 10 months of abstinence at the moment of participating in the study. Regarding common medical conditions associated with AUD, we observed an elevated incidence of alcohol-induced liver and pancreas diseases (18.7%) and psychiatric comorbidity (76.9%). Thus, AUD patients displayed a high prevalence of dual diagnosis (39.3%) [mainly depression (19.9%)] and comorbid substance use disorders (40.7%). Plasma BDNF and IGF-1 concentrations were significantly lower in the alcohol group than in the control group (p
dc.format.number11es_ES
dc.format.pagee0187634es_ES
dc.format.volume12es_ES
dc.identifier.doi10.1371/journal.pone.0187634
dc.identifier.e-issn1932-6203es_ES
dc.identifier.journalPloS onees_ES
dc.identifier.otherhttp://hdl.handle.net/10668/11773
dc.identifier.pubmedID29108028es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17344
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult
dc.subject.meshAlcohol-Related Disorders
dc.subject.meshBiomarkers
dc.subject.meshBrain-Derived Neurotrophic Factor
dc.subject.meshCase-Control Studies
dc.subject.meshCross-Sectional Studies
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInsulin-Like Growth Factor Binding Protein 3
dc.subject.meshInsulin-Like Growth Factor I
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshSubstance Withdrawal Syndrome
dc.titleDecreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files